The most common prescription drugs for people with Alzheimer’s disease are now approved to treat symptoms such as memory loss, mood changes and depression, with the hope that by stopping them, their symptoms will be treated sooner.

While the medications are being used to help patients with mild cognitive impairment or mild cognitive dysfunction, they’re also being used in more serious cases.

In March, the Food and Drug Administration approved a blockbuster anti-epilepsy drug for $12,000.

The drug is being marketed by Novartis, a Swiss pharmaceutical giant.

The drug is used to treat patients with a milder form of the disease called Dravet syndrome, in which patients have seizures and memory loss that are associated with dementia.

While it’s still a relatively rare disease, Alzheimer’s patients are experiencing a surge in seizures, seizures that occur in response to a mild cognitive disturbance or memory loss.

The medication can be used to relieve seizures.

But it’s not known if it will work as a treatment for Alzheimer’s, or if it would prevent people from losing memories.

Novartis and other drugmakers have said the drugs would help patients in their later stages of the disorder.

The drugs have not been tested in people with dementia or Alzheimer’s.

The company said its research showed that the drug helped improve memory, and it had shown that it could prevent memory loss in patients with the disorder who had seizures and who had suffered a loss of memory.

But Dr. David Vassallo, a professor of neurology at Stanford University and a leading expert on Alzheimer’s and Dravets, said he didn’t know whether the drugs could help people who didn’t have seizures or memory problems.

If they can’t help patients who have those symptoms, then there are a lot of people who have dementia who are going to end up in the hospital for a long time, and they have to be monitored very closely, he said.

We don’t know how well they are working in the patients with seizures, Vassalo said.

If it works in those patients, I think it would be a good thing to use it.

If patients with Dravetis or memory losses don’t have that, then they are going have a difficult time, he added.

Vassallo said the company would also be testing the drugs in people who were suffering from seizures.

He said he did not know if the drugs were safe for those people.

He also noted that a recent study published in the journal Neurology found that the drugs may impair the brain.

People are already starting to get more aggressive in their treatment of Dravetz syndrome, he noted.

That’s been particularly true in patients who are younger and older.

People who are taking the drug are not going to be able to stop their seizures because they have a mild impairment of their memory, he pointed out.

We’re going to need a lot more of them to see whether they are able to treat the memory loss and the cognitive impairment.

People should be on the front lines, not in the back, Vasallo said.

For people who are older, the drugs are going not to be effective.

They’re going not going be able, he warned.

The study was done in patients older than 65 years old who were treated with a combination of the drugs.

The people who received the drugs had a median of two years to live.

In the trial, people were treated by doctors with a minimum of two weeks between each treatment.

People with epilepsy and the other types of dementia were excluded from the study.

The results of the trial are expected to be published next month, according to the FDA.

The FDA also approved a drug last month for $6,500 for people who had mild dementia.

It is being tested in a phase II study of the drug in people over the age of 65.

The Drug Enforcement Administration said last month that it was approving a drug to treat people with a form of dementia called dementia amyloidosis that was also linked to memory loss or memory impairment.

That drug is called Ritalin.

It costs about $30,000 a year.

The drugs were approved to combat memory loss associated with Alzheimerís disease.

They are being sold by AstraZeneca, a U.S. biopharmaceutical company, and have been approved for Alzheimer`s patients.